In brief, these studies showed excellent biochemical control rates after 1–5 years in the range of 93–100% for low and intermediate risk prostate cancers (PSA value < 20 ng/ml and Gleason score ≤ 7). This evidence concerns the gene KLK3 and prostate carcinoma.